Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

50%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(1)

Detailed Status

Completed2

Withdrawn1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 11 (33.3%)

N/A2 (66.7%)

Trials by Status

completed250%

withdrawn125%

active_not_recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingnot_applicable

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

NCT05455606

withdrawnphase_1

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

NCT05490381

completed

HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program

NCT02616133

completednot_applicable

NCCN Renal Cell Registry

NCT02677337

Clinical Trials (4)

Showing 4 of 4 trials

NCT05455606Not Applicable

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Active Not Recruiting

NCT05490381Phase 1

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

Withdrawn

NCT02616133

HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program

Completed

NCT02677337Not Applicable

NCCN Renal Cell Registry

Completed

All 4 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 4